Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation

NCT03573908 is registered in ClinicalTrials.gov with Ironwood Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03573908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03573908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 20, 2018
Completion date
April 10, 2019
Enrollment
614 (actual)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome characterized by constipation